Citations 33
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
Shah, Nirav N. , Ahn, Kwang Woo , Litovich, Carlos, Fenske, Timothy S. , Ahmed, Sairah , Bejanyan, Nelli , Bolaños‐Meade, Javier , Chen, Andy I. , Ciurea, Stefan O. , Bachanová, Veronika , DeFilipp, Zachariah , Epperla, Narendranath , Farhadfar, Nosha , Herrera, Alex F. , Haverkos, Bradley M. , Holmberg, Leona , Hossain, Nasheed , Kharfan‐Dabaja, Mohamed A. , Kenkre, Vaishalee P. , Murthy, Hemant S. , Rezvani, Andrew R. , D’Souza, Anita , Ulrickson, Matthew L. , Waller, Edmund K. , Sureda, Anna , Smith, Sonali M. , Holmberg, Leona , Chen, Andy , Kharfan-Dabaja, Mohamed A., D'Souza, Anita , Bachanova, Veronika , Murthy, Hemant S , Waller, Edmund K , Epperla, Narendranath , Ahmed, Sairah , Battiwalla, Minoo , Dahi, Parastoo B , Lazarus, Hillard M. , Nishihori, Taiga , Savani, Bipin N. , Hamadani, Mehdi
Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 933-940
10.1182/bloodadvances.2018018531
Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.
Acute leukemia in pregnancy: a single institution experience with 23 patients
Farhadfar, Nosha , Cerquozzi, Sonia , Hessenauer, M.R., Litzow, Mark R. , Letendre, Louis, Patnaik, Mrinal M. , Tefferi, Ayalew , Gangat, Naseema , Hessenauer, Michael R, Hogan, William J.
Leukemia & Lymphoma | August 26, 2016 | Volume: 58 | Issue: 5 | Pages: 1052-1060
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
Farhadfar, Nosha , Cerquozzi, Sonia , Patnaik, Mrinal M. , Tefferi, Ayalew
Journal of Oncology Practice | July 12, 2016 | Volume: 12 | Issue: 7 | Pages: 611-621
Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in shortened survival and leukemic transformation. It is a disease predominantly of the elderly, and currently available therapies only offer symptom control without curative benefit or ability to alter disease progression. Allogeneic hematopoietic stem-cell transplant (HSCT) is the only potentially curative intervention; however, this is only feasible in younger and medically fit patients and selectively offered to those with high-risk disease. Despite ongoing advancements, HSCT is associated with substantial morbidity and mortality, and the determination of which patients with myelofibrosis are ideal candidates and the selection of the opportune moment to proceed with transplantation remains challenging. This review summarizes our current recommendations for the role of and indications for HSCT in myelofibrosis.